Researchers will compare these effects to those in patients who are getting hormone therapy alone.

Tag Stein, MD, medical oncologist at CINJ and associate professor of medicine at UMDNJ-Robert Wood Johnson Medical School, may be the lead CINJ researcher on the brand new study. With growing use of immune therapy to take care of advanced types of prostate cancers, there is great interest in exploring the effect that this kind of treatment could have on the disease at a pre-metastatic stage, he stated. Related StoriesNew RNA check of blood platelets can be used to identify location of cancerFDA grants accelerated approval for Tagrisso to take care of patients with advanced NSCLCNew vaccine appears to be more effective in reducing 'bad' LDL cholesterolAdults who are identified as having prostate cancer that’s unresponsive to hormone therapy rather than visible on imaging checks such as a CT scan and a bone scan, and have a rising PSA level, meet the criteria to be a part of the trial, although additional criteria must be met.‘These leading researchers, who have been in the vanguard of scientific developments in Alzheimer’s disease, possess devoted their professional careers to greater understanding of this disease.’ Lifetime Accomplishment Awards in Alzheimer’s Disease Research Henry Wisniewski, MD, PhD; Khalid Iqbal, PhD; and Bengt Winblad, MD, PhD, founded AAICAD in 1988. Lifetime Accomplishment Awards named in their honor are given to three outstanding researchers who have dedicated their careers to helping millions all over the world through their research. At AAICAD 2010, the 2010 Henry Wisniewski Life time Achievement Award was provided to Dr. Takehsi Iwatsubo, whose significant research with japan Alzheimer’s Disease Neuroimaging Initiative can be creating a longitudinal workup of standardized neuroimaging, biomarker and clinico-psychological surveys.